These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 19283922)

  • 21. Controversies in the surgical management of GIST in the era of imatinib.
    Raut CP; Bertagnolli MM
    Oncology (Williston Park); 2009 Jan; 23(1):69, 74-6. PubMed ID: 19283924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal stromal tumors: current management.
    Pisters PW; Patel SR
    J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIT mutations in GIST.
    Fletcher JA; Rubin BP
    Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
    Montemurro M; Bauer S
    Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
    Martínez-Marín V; Maki RG
    Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib treatment for gastrointestinal stromal tumour (GIST).
    Lopes LF; Bacchi CE
    J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 31. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib.
    Murray M; Hatcher H; Jessop F; Williams D; Carroll N; Bulusu R; Judson I
    Pediatr Blood Cancer; 2008 Feb; 50(2):386-8. PubMed ID: 17729245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
    Marano L; Boccardi V; Marrelli D; Roviello F
    Eur J Surg Oncol; 2015 Jul; 41(7):814-22. PubMed ID: 25956211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
    von Mehren M
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
    J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
    Pantaleo MA; Nannini M; Di Battista M; Catena F; Biasco G
    Cancer Treat Rev; 2010 Feb; 36(1):63-8. PubMed ID: 19914780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.